Literature DB >> 25653093

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Andrea Lunardi1, Shohreh Varmeh1, Ming Chen1, Riccardo Taulli1, Jlenia Guarnerio1, Ugo Ala1, Nina Seitzer1, Tomoki Ishikawa1, Brett S Carver2, Robin M Hobbs1, Valentina Quarantotti1, Christopher Ng1, Alice H Berger1, Caterina Nardella1, Laura Poliseno1, Rodolfo Montironi3, Mireia Castillo-Martin4, Carlos Cordon-Cardo4, Sabina Signoretti5, Pier Paolo Pandolfi6.   

Abstract

UNLABELLED: The ETS family of transcription factors has been repeatedly implicated in tumorigenesis. In prostate cancer, ETS family members, such as ERG, ETV1, ETV4, and ETV5, are frequently overexpressed due to chromosomal translocations, but the molecular mechanisms by which they promote prostate tumorigenesis remain largely undefined. Here, we show that ETS family members, such as ERG and ETV1, directly repress the expression of the checkpoint kinase 1 (CHK1), a key DNA damage response cell-cycle regulator essential for the maintenance of genome integrity. Critically, we find that ERG expression correlates with CHK1 downregulation in human patients and demonstrate that Chk1 heterozygosity promotes the progression of high-grade prostatic intraepithelial neoplasia into prostatic invasive carcinoma in Pten(+) (/-) mice. Importantly, CHK1 downregulation sensitizes prostate tumor cells to etoposide but not to docetaxel treatment. Thus, we identify CHK1 as a key functional target of the ETS proto-oncogenic family with important therapeutic implications. SIGNIFICANCE: Genetic translocation and aberrant expression of ETS family members is a common event in different types of human tumors. Here, we show that through the transcriptional repression of CHK1, ETS factors may favor DNA damage accumulation and consequent genetic instability in proliferating cells. Importantly, our findings provide a rationale for testing DNA replication inhibitor agents in ETS-positive TP53-proficient tumors. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653093      PMCID: PMC6010310          DOI: 10.1158/2159-8290.CD-13-1050

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  69 in total

1.  Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability.

Authors:  Vessela Vassileva; Anna Millar; Laurent Briollais; William Chapman; Bharati Bapat
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

Review 2.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

Review 3.  DNA damage checkpoints in stem cells, ageing and cancer.

Authors:  Tobias Sperka; Jianwei Wang; K Lenhard Rudolph
Journal:  Nat Rev Mol Cell Biol       Date:  2012-09       Impact factor: 94.444

4.  Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.

Authors:  A Menoyo; H Alazzouzi; E Espín; M Armengol; H Yamamoto; S Schwartz
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

5.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

6.  CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers.

Authors:  F Bertoni; A M Codegoni; D Furlan; M G Tibiletti; C Capella; M Broggini
Journal:  Genes Chromosomes Cancer       Date:  1999-10       Impact factor: 5.006

7.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

8.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.

Authors:  Mike I Walton; Paul D Eve; Angela Hayes; Melanie R Valenti; Alexis K De Haven Brandon; Gary Box; Albert Hallsworth; Elizabeth L Smith; Kathy J Boxall; Michael Lainchbury; Thomas P Matthews; Yann Jamin; Simon P Robinson; G Wynne Aherne; John C Reader; Louis Chesler; Florence I Raynaud; Suzanne A Eccles; Ian Collins; Michelle D Garrett
Journal:  Clin Cancer Res       Date:  2012-08-28       Impact factor: 12.531

10.  Chk1 regulates the density of active replication origins during the vertebrate S phase.

Authors:  Apolinar Maya-Mendoza; Eva Petermann; David A F Gillespie; Keith W Caldecott; Dean A Jackson
Journal:  EMBO J       Date:  2007-05-10       Impact factor: 11.598

View more
  12 in total

1.  Mitochondrial Membrane Potential Regulates Nuclear Gene Expression in Macrophages Exposed to Prostaglandin E2.

Authors:  David E Sanin; Mai Matsushita; Ramon I Klein Geltink; Katarzyna M Grzes; Nikki van Teijlingen Bakker; Mauro Corrado; Agnieszka M Kabat; Michael D Buck; Jing Qiu; Simon J Lawless; Alanna M Cameron; Matteo Villa; Francesc Baixauli; Annette E Patterson; Fabian Hässler; Jonathan D Curtis; Christina M O'Neill; David O'Sullivan; Duojiao Wu; Gerhard Mittler; Stanley Ching-Cheng Huang; Erika L Pearce; Edward J Pearce
Journal:  Immunity       Date:  2018-12-18       Impact factor: 31.745

2.  Effective intra-S checkpoint responses to UVC in primary human melanocytes and melanoma cell lines.

Authors:  Marila Cordeiro-Stone; John J McNulty; Christopher D Sproul; Paul D Chastain; Eugene Gibbs-Flournoy; Yingchun Zhou; Craig Carson; Shangbang Rao; David L Mitchell; Dennis A Simpson; Nancy E Thomas; Joseph G Ibrahim; William K Kaufmann
Journal:  Pigment Cell Melanoma Res       Date:  2015-11-03       Impact factor: 4.693

Review 3.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

4.  Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Authors:  Sandra M Lopez; Alexander I Agoulnik; Manqi Zhang; Leif E Peterson; Egla Suarez; Gregory A Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Clin Cancer Res       Date:  2016-03-11       Impact factor: 12.531

5.  The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.

Authors:  Payel Chatterjee; Gaurav S Choudhary; Turkeyah Alswillah; Xiahui Xiong; Warren D Heston; Cristina Magi-Galluzzi; Junran Zhang; Eric A Klein; Alexandru Almasan
Journal:  Mol Cancer Ther       Date:  2015-05-29       Impact factor: 6.261

6.  Distinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticity.

Authors:  Anastasia V Rulina; Frédérique Mittler; Patricia Obeid; Sophie Gerbaud; Laurent Guyon; Eric Sulpice; Frédérique Kermarrec; Nicole Assard; Monika E Dolega; Xavier Gidrol; Maxim Y Balakirev
Journal:  Cell Death Dis       Date:  2016-12-01       Impact factor: 8.469

7.  Chk1 Promotes DNA Damage Response Bypass following Oxidative Stress in a Model of Hydrogen Peroxide-Associated Ulcerative Colitis through JNK Inactivation and Chromatin Binding.

Authors:  Kathrin Reissig; Andrew Silver; Roland Hartig; Antje Schinlauer; Diana Walluscheck; Thomas Guenther; Sandra Siedentopf; Jochen Ross; Diep-Khanh Vo; Albert Roessner; Angela Poehlmann-Nitsche
Journal:  Oxid Med Cell Longev       Date:  2017-06-07       Impact factor: 6.543

Review 8.  Roles and regulations of the ETS transcription factor ELF4/MEF.

Authors:  Mary Ann Suico; Tsuyoshi Shuto; Hirofumi Kai
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

Review 9.  Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors.

Authors:  Musaffe Tuna; Christopher I Amos; Gordon B Mills
Journal:  Oncotarget       Date:  2019-03-12

10.  Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma.

Authors:  Er-Bao Chen; Shao-Lai Zhou; Xu-Guang Pang; Dan Yin; Pei-Zhen Miao; Yi Yang; Qing Chen; Kai Zhu; Dong-Mei Gao; Tian-Shu Liu; Xiao-Yi Wang; Ying-Hong Shi; Wei-Zhong Wu; Jian Zhou; Zheng-Jun Zhou; Zhi Dai
Journal:  Oncotarget       Date:  2017-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.